Research Projects & Grants

For Profit Organization

  • Managed Access Program (MAP) to supply CDZ173, Role: Principal Investigator, Novartis Pharmaceuticals Corporation, Status: Awarded
  • (CDA) Pharming Technologies / Dr. Barbara Ariue, Role: PD/PI, Pharming Technologies B.V., Status: Awarded

Other Research

  • IRB Approved. HS 5190425. PI. Compassionate use of CDZ173 (Leniolisib) PI for compassionate use of Leniolizib- PI3Kinase inhibitor for patient with severe immunodeficiency with PASLI and CNS lesions. (12/2019 - Present)